Ipsen drug approved by FDA for early pancreatic cancer
BioPharma
Source: biopharmadive.com
📰 Gi Oncology Program News
Gi Oncology Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Gi Oncology Program. Real-time updates on events, politics, business and more.
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium
/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...
Source: prnewswire.com
Camrelizumab With Rivoceranib Elicits PFS and OS Benefit Over Sorafenib in Unresectable HCC
Amit Mahipal, MD, discusses clinical outcomes with camrelizumab plus rivoceranib as first-line treatment in unresectable HCC, based on data from the randomized, open-label, international phase 3 CARES-310 trial.
United States Amit Mahipal Gi Oncology Program University Hospitals In Rochester Case Western Reserve University University Hospitals
Source: onclive.com
Test Predicts Which CRC Patients Benefit from Adjuvant Chemo
Testing for molecular residual disease was able to identify patients with early-stage colorectal cancer who are most likely to benefit from adjuvant chemotherapy.
Source: medscape.com
Dr Neil Sharma Offers State-of-the-art Care for Pancreatic Cancer
Every year, over 60,000 people develop new cases of pancreatic cancer, with nearly 48,000 dying every year from this disease. Dr. Neil Sharma MD of Parkview
United States Dr Neil Sharma Research Symposium Gi Oncology Program Parkview Cancer Institute Parkview Health Parkview Health Treats Pancreatic Cancer
Source: einnews.com
Curis Announces Gastroenterolo - GuruFocus.com
GuruFocus Article or News written by PRNewswire and the topic is about:
James Dentzer Gi Oncology Program Drug Administration Washington University School Of Medicine Curis Inc Exchange Commission
Source: gurufocus.com